HC Wainwright Has Bearish Outlook for CRDL FY2025 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Research analysts at HC Wainwright reduced their FY2025 earnings estimates for Cardiol Therapeutics in a report issued on Monday, April 7th. HC Wainwright analyst V. Bernardino now expects that the company will post earnings of ($0.47) per share for the year, down from their previous forecast of ($0.33). HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share.

Several other brokerages also recently weighed in on CRDL. Rodman & Renshaw initiated coverage on Cardiol Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $7.00 price target on the stock. RODMAN&RENSHAW raised Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Cardiol Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.40.

Cardiol Therapeutics Stock Up 6.8 %

Shares of NASDAQ CRDL opened at $0.96 on Thursday. Cardiol Therapeutics has a 1 year low of $0.77 and a 1 year high of $3.12. The firm has a 50-day simple moving average of $1.11 and a two-hundred day simple moving average of $1.43. The company has a market cap of $79.06 million, a P/E ratio of -2.45 and a beta of 1.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49.

Cardiol Therapeutics (NASDAQ:CRDL) last released its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01.

Institutional Trading of Cardiol Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. PVG Asset Management Corp purchased a new position in Cardiol Therapeutics during the 4th quarter worth $624,000. Cetera Investment Advisers bought a new position in shares of Cardiol Therapeutics during the 4th quarter worth $56,000. Envestnet Asset Management Inc. purchased a new position in shares of Cardiol Therapeutics during the fourth quarter valued at $398,000. Virtu Financial LLC purchased a new position in shares of Cardiol Therapeutics during the fourth quarter valued at $61,000. Finally, Tejara Capital Ltd raised its holdings in shares of Cardiol Therapeutics by 75.9% in the fourth quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company’s stock valued at $3,988,000 after acquiring an additional 1,344,167 shares in the last quarter. Institutional investors own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.